Pegylated interferon alfa-2b as treatment of solid tumors

被引：3
|
作者：
Ronald M. Bukowski
机构：
来源：
Current Oncology Reports | 2003年 / 5卷 / 2期
关键词：
Melanoma; Renal Cell Carcinoma; Clin Oncol; Sustained Virologic Response; Maximum Tolerate Dose;
D O I：
10.1007/s11912-003-0094-7
中图分类号：
学科分类号：
摘要：
PEG-IFN á-2b is active in patients with metastatic RCC and melanoma and is tolerated well at doses up to 6.0 μg/kg/wk. This trial provides a rationale for further studies using this pegylated cytokine alone or in combination with such agents as interleukin (IL)-2.
引用
收藏
页码：87 / 88
页数：1
相关论文
共 50 条
  • [1] Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study
    Bukowski, R
    Ernstoff, MS
    Gore, ME
    Nemunaitis, JJ
    Amato, R
    Gupta, SK
    Tendler, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3841 - 3849
  • [2] Thyrotoxicosis With Pegylated Interferon Alfa-2b
    Lowndes, Sarah A.
    Asher, Ruth
    Middleton, Mark R.
    ARCHIVES OF DERMATOLOGY, 2010, 146 (11) : 1273 - 1275
  • [3] Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C
    Trepo, C
    Lindsay, K
    Niederau, C
    Shiffman, M
    Gordon, S
    Hoefs, J
    Schiff, E
    Marcellin, P
    Bacon, B
    Fang, J
    Garaud, J
    Albrecht, J
    JOURNAL OF HEPATOLOGY, 2000, 32 : 29 - 29
  • [4] Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
    Jen, JF
    Glue, P
    Ezzet, F
    Chung, C
    Gupta, SK
    Jacobs, S
    Hajian, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) : 407 - 421
  • [5] Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin
    Deutsch, M
    Koskinas, J
    Tzannos, K
    Vassilopoulos, D
    Mailis, A
    Tolis, G
    Hadziyannis, S
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1745 - 1748
  • [6] A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
    Lindsay, KL
    Trepo, C
    Heintges, T
    Shiffman, ML
    Gordon, SC
    Hoefs, JC
    Schiff, ER
    Goodman, ZD
    Laughlin, M
    Yao, RJ
    Albrecht, JK
    HEPATOLOGY, 2001, 34 (02) : 395 - 403
  • [7] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    Rao, P. N.
    Koshy, Abraham
    Philip, Jacob
    Premaletha, Narayanan
    Varghese, Joy
    Narayanasamy, Krishnasamy
    Mohindra, Samir
    Pai, Nitin Vikas
    Agarwal, Manoj Kumar
    Konar, Ashoknanda
    Vora, Hasmukh B.
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (07) : 520 - 526
  • [8] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    PN Rao
    Abraham Koshy
    Jacob Philip
    Narayanan Premaletha
    Joy Varghese
    Krishnasamy Narayanasamy
    Samir Mohindra
    Nitin Vikas Pai
    Manoj Kumar Agarwal
    Ashokna Konar
    Hasmukh B Vora
    World Journal of Hepatology, 2014, (07) : 520 - 526
  • [9] Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C
    Michael R Kraus
    Arne Sch(a|¨)fer
    Herbert Csef
    Michael Scheurlen
    World Journal of Gastroenterology, 2005, (12) : 1769 - 1774
  • [10] Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C
    Kraus, Michael R.
    Schaefer, Arne
    Csef, Herbert
    Scheurlen, Michael
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (12) : 1769 - 1774
12345